This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EVT 401

Evotec AG

Drug Names(s): P2X7 Antagonist

Description: Evotec's P2X7 antagonist is a novel small molecule. The P2X7 receptor is a member of a family of ligand-gated ion channels and is found primarily in cells of the immune systems where it is thought to play a role in inflammatory processes. As it has been shown to initiate the processing and release of the IL-1 family of cytokines, it is believed to play a critical role in the inflammation. The receptor has been implicated in the dependent lysis of macrophages. It may also be found in the central nervous system.

Deal Structure: Evotec and Conba
In May 2012, Evotec and Conba Pharmaceutical announced the grant of a development and marketing license on EVT 401 for human indications with exception of ophthalmological, chronic obstructive pulmonary disease (COPD) and endometriosis in China. Evotec receives a small upfront payment, development and commercial milestone payments in excess of EUR 60 m, and tiered double-digit royalties on net sales. The agreement grants Conba Pharmaceutical exclusive rights to develop and commercialise the compound for the Chinese market. Evotec will have the right to reference clinical data produced by Conba Pharmaceutical to support potential further development of EVT 401 in other territories.

Partners: Zhejiang Conba Pharmaceutical Co., Ltd.


EVT 401 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug